Boston Scientific(NYSE:BSX), a medical device developer, closed Wednesday at $64.87, up 8.99%. The stock is jumping after a Q1 earnings beat paired with lowered 2026 guidance. Investors are watching how the reset targets shape growth expectations and valuation. Trading volume reached 40.4 million shares, about 138% above its three-month average of 17 million shares. Boston Scientific IPO'd in 1992 and has grown 1,415% since going public.
How the markets moved today
S&P 500 rose 1.03% to 7,137, while the Nasdaq Composite advanced 1.64% to 24,658. Within medical devices, industry peers Medtronic closed at $83.22 (+1.49%) and Stryker finished at $329.35 (+0.63%), showing more muted gains than Boston Scientific.
What this means for investors
Boston Scientific reported Q1 earnings this morning that saw sales and adjusted EPS rise 9% and 6%, slipping past Wall Street’s estimates. Despite lowering its full-year sales growth guidance from 10.5% to 7.25% at the midpoint, BSX shares rallied 9% higher today.
While this may seem peculiar at first glance, it is worth noting that BSX stock has gone through the wringer recently, and its shares are still down 37% over the last six months alone -- even after today’s increase. After releasing underwhelming clinical trial data on its Watchman heart implant three weeks ago -- and disappointing with earnings in February -- today’s earnings seemed “good enough” for a company trading at just 19 times forward earnings.
Boston Scientific remains an intriguing stock to me amid its decline, and may interest medical device-savvy investors.
Should you buy stock in Boston Scientific right now?
Before you buy stock in Boston Scientific, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Boston Scientific wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $499,277!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,225,371!*
Now, it’s worth noting Stock Advisor’s total average return is 972% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 22, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Medtronic. The Motley Fool has a disclosure policy.
